Craft

Inhibitor Therapeutics

Stock Price

$0.1

2024-10-29

Market Capitalization

$12.9 M

2024-10-29

Inhibitor Therapeutics Summary

Company Summary

Overview
Inhibitor Therapeutics (formerly known as HedgePath Pharmaceuticals) is a pharmaceutical company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. It develops SUBA-Itraconazole, a patented, oral formulation of the currently marketed, anti-fungal drug, Itraconazole, for treatment of prostate and lung cancers.
Type
Public
Status
Active
Founded
1992
HQ
Tampa, FL, US | view all locations
Website
https://inhibitortx.com/
Cybersecurity rating
Sectors

Key People

  • Nicholas J. Virca

    Nicholas J. Virca, President and Chief Executive Officer

    • Garrison J. Hasara

      Garrison J. Hasara, Chief Financial Officer, Treasurer, Corporate Secretary, Chief Compliance Officer

      • Amy McCord

        Amy McCord, Vice President, Regulatory Affairs

      LocationsView all

      1 location detected

      • Tampa, FL HQ

        United States

        449 S 12th St #1705

      Inhibitor Therapeutics Financials

      Summary Financials

      Net income (Q3, 2024)
      ($731.0K)
      Cash (Q3, 2024)
      $6.4M
      EBIT (Q3, 2024)
      ($813.2K)

      Footer menu